Abstract
Purpose
Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide and caused mortality. Many factors have been reported to affect the prognosis of COVID-19. In this study, we aimed to investigate the effects of drug therapy and vaccination on prognosis in patients hospitalized with a COVID-19 diagnosis.
Methods
In this single-center, cross-sectional study, data were retrospectively collected from patients receiving inpatient treatment at a university hospital with a diagnosis of COVID-19 between January 1, 2020, and April 30, 2022. The patients’ demographic and clinical characteristics were recorded. The Chi-square, Cox and logistic regression was performed, P < 0.05 was considered statistically significant.
Results
Total 1723 patients (50.1% were men, mean age: 60.6 ± 16.90) who had not been vaccinated rate was 27.0% (> 3 doses: 45.7%). Mortality rate was 17.0%. Increasing age, male, a high Charlson Comorbidity Index (CCI), and no vaccination significantly increased mortality (P < 0.05). The mortality rate was significantly lower in the chloroquine treatment group than in the other treatment groups. Increasing age, male, and a high CCI were determined to be factors that significantly increased the length of hospital stay (LOHS). LOHS found to be significantly lower in the favipiravir or chloroquine groups compared to the remaining treatment groups (P < 0.001). Both mortality and the LOHS significantly differed according to AST, d-dimer, ferritin, and GFR.
Conclusion
This study primarily investigated the effect of treatment and vaccination on the prognosis of COVID-19. This was determined to be prepared for another potential pandemic that may arise due to COVID-19.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) virus caused the development of coronavirus disease 2019 (COVID-19) and resulted in a pandemic by spreading across the world in a short time (Lu et al. 2020). The World Health Organization (WHO) declared COVID-19 as an emergency of international concern (Sohrabi et al. 2020). COVID-19 has affected more than 200 countries, causing the deaths of 6.5 million people in the world, including more than 100 thousand people in Turkey (Chakraborty and Maity 2020; Cascella et al. 2023; Adalja et al. 2020; Zeren and Yilanci 2020). Although all age groups are at risk for contracting COVID-19, it has been observed that especially elderly patients and those with comorbidities such as diabetes, asthma, chronic obstructive pulmonary disorder, hypertension, and coronary artery disease have a more severe disease course (Hernández-Galdamez et al. 2020).
COVID-19 has different clinical manifestations in humans, ranging from mild symptoms, such as weakness and signs of upper respiratory tract infection to mortality due to acute respiratory failure (Wiersinga et al. 2020). With the rapid spread of the disease, agents to be used in the treatment were rapidly tested in clinical studies and introduced into clinical use. Currently, the primary treatments for the disease are antiviral drugs, immunomodulators, neutralizing antibodies, and cell and gene therapies (Niknam et al. 2022). Combination therapies have also been shown to have more advantages (Yuan et al. 2023).
Studies have been conducted to predict the prognosis of COVID-19, and significant results have been obtained regarding lymphopenia and eosinopenia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, ferritin, and d-dimer (Kermali et al. 2020; Lagunas-Rangel 2020; Yao et al. 2020; Valverde-Monge et al. 2021). Male gender, older age, smoking, diabetes, hypertension, and cardiovascular or respiratory system diseases have been determined to be prognostic factors that may cause COVID-19 to have a more severe course and increase the mortality rate (Zhang et al. 2022). In addition, it has been reported that socioeconomic status, diet, lifestyle, geographical differences, ethnicity, viral load exposure, onset of treatment, and quality of healthcare services also affect individual outcomes (Gao et al. 2021). However, only a few studies have investigated the relationship between drugs used in the treatment of COVID-19 and disease prognosis among inpatients (Alotaibi et al. 2021). In addition, considering the increasing vaccination rates across the world, there is a need for a multifactorial study to evaluate the relationship between vaccination and COVID-19 prognosis.
This study aimed to investigate the effects of drugs used in the treatment of COVID-19 (chloroquine and favipiravir), vaccination status and doses, laboratory parameters, demographic characteristics, and the Charlson Comorbidity Index on prognosis [length of hospital stay (LOHS) and mortality] in patients admitted to the hospital with a diagnosis of COVID-19.
Methods
In this single-center, descriptive, cross-sectional, non-interventional study, the data of inpatients diagnosed with COVID-19 at the Health Application and Research Center of Afyonkarahisar Health Sciences University (AFSU) between January 1, 2020, and April 30, 2022 were retrospectively recorded from the hospital’s electronic system. The study was initiated after the approval of Afyonkarahisar University of Health Sciences (AFSU) Non-Interventional Research Ethics Committee and Ministry of Health (Turkey). In accordance with the Regulation on the Processing and Privacy of Personal Health Data and the principles of the Declaration of Helsinki, all identity information of the patients was anonymized.
The data of a total of 1892 inpatients with COVID-19 were retrospectively collected. Since a patient may have had more than one presentation, each visit was evaluated separately. No sample was selected, and all inpatients treated within 1 year were included in the study.
The inclusion criteria were as follows: (a) diagnosis of COVID-19 based on a positive polymerase chain reaction test or clinical and radiological (thoracic computed tomography or chest X-ray) findings; (b) receiving inpatient treatment; (c) age of 18 years or over; and (d) taking at least one drug during hospitalization. Excluded from the study were patients who were referred to another center and therefore could not be followed up, as well as those with missing data. After applying these criteria, the data of 1723 patients were included in the study (Fig. 1).
The independent variables were the patients’ demographic characteristics (age and gender), comorbidities, Charlson Comorbidity Index (CCI) values, biochemical laboratory findings measured on the first day [creatinine, glomerular filtration rate (GFR), aspartate aminotransferase (AST), alanine transaminase (ALT), d-dimer, and ferritin], COVID-19 vaccine status, and drug therapy used for the treatment of COVID-19. The reference ranges of the hospitals were taken into account when evaluating the laboratory results. The dependent variable was disease prognosis, for which mortality status and LOHS were recorded.
The vaccines administered for COVID-19 in the study group were mRNA-based BioNTech (Pfizer/BioNTech Fosun Pharma), inactivated CoronaVac (Sinovac Research and Development Co. Ltd.), and inactivated Turkovac (Erciyes University and Health Institutes of Turkey). Only the presence/absence of vaccination and the number of vaccination doses (one to four) were recorded for each patient.
Descriptive data were presented as number (n), percentage (%), and mean (standard deviation) values. Age, LOHS, and laboratory findings were evaluated by dividing the median values into two groups. CCI, a parameter used to predict 1-year mortality, was analyzed in two groups (CCI < 1 and CCI ≥ 1). COVID-19 treatment was divided into four groups: favipiravir (FVP), chloroquine (CLQ), FVP + CLQ, and standard therapy (ST) (not including FVP or CLQ). The conformity of the data to the normal distribution was checked with the Shapiro–Wilk test. The relationship between dependent and independent variables was evaluated with the Chi-square test. Cox regression analysis was used for mortality, and logistic regression analysis was performed for LOHS. Variables that had a significant relationship in the univariate analysis were included in the multivariate models. For the highly correlated variables, one was included in these models (e.g., GFR or creatinine and AST or ALT). Data were analyzed using SPSS v. 24 (SPSS Inc., Chicago, IL, USA) statistical software. A P value of P < 0.05 was considered statistically significant.
Results
Demographic characteristics of patients
The mean age of the 1723 patients included in the study was 60.6 ± 16.90 years, and 50.1% of the patients (n = 863) were male. The most common comorbidity was hypertension at a rate of 23.7%, followed by diabetes mellitus at 15.8%. CCI was calculated to be 0 in 68.8% (n = 186) of the patients. The rate of patients who had not been vaccinated for COVID-19 was 27.0% (n = 465), while 3.9% (n = 68) of the patients had received one vaccination dose, 23.4% (n = 403) two doses, and 45.7% (n = 787) three or more doses. The rate of patients who received FVP and/or CLQ treatment was 66.7% (n = 1150). The median LOHS was 6 days (min: 1-max: 58). Mortality developed in 17.0% (n = 293) of the patients.
Comparison of clinical outcomes
When the factors affecting mortality were examined, it was found that increasing age, male gender, the absence of COVID-19 vaccination, and a high CCI significantly increased mortality, while the mortality rate significantly decreased as the number of COVID-19 vaccination doses increased (linear trend, P < 0.001).
There was a significant difference in mortality between the treatment groups (Table 1). When the groups were compared, the mortality rate was significantly lower in the CLQ group than in the remaining treatment groups. There was a significant decrease in mortality in the group that received FVP treatment compared to the group that received ST alone. No significant difference was found in mortality between the remaining treatment groups (not included in tables).
The factors affecting LOHS were found to be similar to those affecting mortality. Increasing age, male gender, and a high CCI significantly increased LOHS. When the vaccination rates were examined, LOHS was significantly higher in the unvaccinated group than in all vaccinated groups (Table 1). However, there was no significant difference in LOHS according to the number of vaccine doses received (Chi-square test, P > 0.05). The hospital stay was determined to be the shortest in the group that received CLQ treatment. LOHS was lower in the FVP or CLQ treatment groups compared to the remaining treatment groups (P < 0.001). Although no significant difference was found between the FVP + CLQ group and the ST group in terms of LOHS, the patients who received FVP + CLQ group had a longer hospital stay compared to those in other treatment groups (Table 1).
Concerning laboratory findings, significant differences were found in both mortality and LOHS in the presence of high AST, d-dimer, and ferritin levels and a low GFR value. Mortality was also significantly affected by a high creatinine level, and LOHS was significantly affected by a high ALT level (Table 2).
Multiple regression analysis for mortality and hospital stay
In the Cox regression analysis, mortality significantly increased with increasing age, AST, and d-dimer values and significantly decreased in the presence of two or more doses of vaccination (Table 3). The logistic regression analysis revealed that increasing age, male gender, a high AST level, and a high ferritin level significantly increased LOHS, while the presence of two or more doses of vaccination or FVP or CLQ treatment significantly reduced LOHS (Table 4).
Discussion
In this study, the data of patients who were diagnosed with COVID-19 and received inpatient treatment at a tertiary university hospital were retrospectively obtained. The relationship of treatments and vaccination status with prognosis was examined, and other factors that could affect the prognosis were also included in the study. Although the mean age of the sample was high since patients aged 18 and under were not included in the study, it was similar to patient ages reported in previous studies conducted in Turkey (Gedik et al. 2023; Kokturk et al. 2021). In our study, as in similar retrospective studies, hypertension and diabetes mellitus were determined to be the two most common comorbidities (Fang et al. 2020; Guisado-Vasco et al. 2020). We found the median LOHS to be 6 days, consistent with previous research indicating that this value ranges from 5 to 17 days (Rees et al. 2020; Alwafi et al. 2021; Birhanu et al. 2022; Guo et al. 2021).
Although both drugs are used in the treatment of COVID-19 with their efficacy having been most clearly shown by clinical studies, CLQ treatment has been abandoned over time as studies on the treatment of COVID-19 have increased (Rattanaumpawan et al. 2022; Tawfik et al. 2022; Cai et al. 2020; Udwadia et al. 2021; Chen et al. 2020; Geleris et al. 2020; Ho et al. 2021). Therefore, in the current study, the rate of patients who had received CLQ treatment was found to be much lower.
Mortality rates were reported to be 2% and 4.5% in two studies conducted with inpatients with COVID-19 in Turkey (Kokturk et al. 2021; Fang et al. 2020), and these values were much lower than the rate we found in our study. However, when COVID-19 inpatients from other countries are examined, this rate ranges from 20.2 to 25.7% (Guisado-Vasco et al. 2020; Quah et al. 2020; Horwitz et al. 2021). In a meta-analysis reviewing similar studies on inpatients with COVID-19, an average mortality rate of 17.1% was found (Macedo et al. 2021), which is very similar to the mortality rate obtained from our study.
We found older age to be an independent risk factor for mortality in COVID-19 patients. Although male gender was significant in the univariate analysis of mortality, it lost its significance in the multivariate analysis. In studies evaluating inpatients with COVID-19 in Turkey, increasing age is observed to be one of the significant risk factors for mortality (Kokturk et al. 2021; Medetalibeyoglu et al. 2020; Birtay et al. 2021). Research results from different countries are similar. In a retrospective study of patients hospitalized with COVID-19 in Brazil, Souza et al. determined that older age and male gender were independent risk factors for mortality (Souza et al. 2021). Multicenter retrospective studies of hospitalized patients from Italy and China also suggest that age is a risk factor for mortality (Bellan et al. 2020; Zhou et al. 2020). Similarly, in a systematic review covering 14 clinical trial meta-analyses, it was reported that older age and male gender were factors that significantly increased mortality (Tian et al. 2020). In another systematic review, age was found to be the factor that most affected mortality (Mehraeen et al. 2020). Older age is one of the most important factors affecting prognosis not only in COVID-19 but in many other diseases.
In this study, there was a significant decrease in mortality with an increase in the number of COVID-19 vaccine doses received, and it was observed that having received two or more doses of vaccination was one of the independent factors affecting mortality. In a systematic review comparing the results of clinical studies using different vaccines, it was stated that there was a significant decrease in mortality rates with vaccination (Huang and Kuan 2022). In a large-scale cohort study conducted in Argentina, it was found that three different vaccines developed for COVID-19 disease significantly reduced mortality (Macchia et al. 2021). Although the design and vaccine types of that study were different from those of our research, the authors reached similar results. In a multicenter observational study conducted in the USA, vaccination was determined to reduce mortality among hospitalized patients (Stepanova et al. 2022). In the current study, 70% of the patients had received at least two vaccine doses, and our results emphasized the importance of not only being vaccinated but also receiving a minimum of two vaccine doses in terms of mortality.
CLQ provided a significant decrease in the mortality rate compared to the remaining treatment groups, while FVP resulted in a significant difference only compared to ST, but both CLQ and FVP had any significant effect on mortality according to the multivariate analysis. In a retrospective study evaluating FVP and CLQ treatments, the mortality rates of the FVP and CLQ groups were determined to be 8.2% and 7.3%, respectively, and although there was a significant difference between these two groups, this significance was not observed in the multivariate analysis (Alotaibi et al. 2021), consistent with our findings. In another retrospective study, Alamer et al. reported that there was no significant difference in mortality between the groups receiving FVP and ST (Alamer et al. 2021). In a study comparing the results of CLQ and a placebo on mortality in hospitalized patients, there was no significant difference in mortality (Self et al. 2020). In our study, similar to the literature, two drug treatments, alone or in combination, had no significant effect on mortality. Studies investigating the effects of drugs and their combinations, such as CLQ + azithromycin, lopinavir, ritonavir, remdesivir, and ivermectin, on the prognosis of COVID-19 are ongoing (Bhimraj et al. 2020).
We found age and male gender to be independent risk factors for LOHS. Similarly, in an observational study conducted in the USA, LOHS was found to be significantly higher in male patients (Nguyen et al. 2021). In a retrospective study conducted in Italy, LOHS was significantly higher in women (Fortunato et al. 2021). In a retrospective study from China, the authors determined LOHS to be significantly longer in older individuals but did not find a significant difference according to gender (Wang et al. 2022). The discrepancies in the results reported from different countries can be attributed to the differences in the ethnic origins of patients.
Similar to mortality, LOHS was significantly lower in the patient group that had received two or more doses of vaccination. The hospital stay was shortened by 40% in the presence of two vaccine doses and by almost 50% in the presence of three doses. In a study conducted in Norway, in which the results of patients who had received at least two doses of an mRNA vaccine and those without a COVID-19 vaccination history were compared, a shorter hospital stay and a lower risk of intensive care unit (ICU) admission were reported in the former (Whittaker et al. 2022). A large-scale descriptive study conducted in the USA reported the LOHS of unvaccinated patients to be longer (Havers et al. 2022). In another large-scale study that was conducted in Italy and included different vaccines, unvaccinated, partially vaccinated, and fully vaccinated groups were compared, and while no significant difference was found between the unvaccinated and partially vaccinated groups in terms of LOHS, the hospital stay was found to be significantly shorter in the fully vaccinated group compared to the remaining groups (Cocchio et al. 2022). The results of our study are in agreement with the literature.
Having received CLQ or FVP treatment was one of the independent factors that resulted in a reduction in LOHS. The reduction in LOHS was much more pronounced in the presence of CLQ treatment. In a multicenter randomized clinical trial with a small number of patients, FVP and CLQ were compared, and no significant difference was found in terms of LOHS (Dabbous et al. 2021). Another multicenter retrospective cohort study compared COVID-19 patients who had and had not received FVP therapy in terms of hospital and ICU stays, a significant decrease was found in the FVP group (Mutair et al. 2022). In a multicenter randomized clinical trial comparing FVP and lopinavir + ritonavir, no significant difference was reported in terms of LOHS (Solaymani-Dodaran et al. 2021). In a randomized clinical trial conducted in China, CLQ and lopinavir + ritonavir were compared, and CLQ was found to reduce LOHS (Huang et al. 2020). According to our results, CLQ treatment caused a significant decrease in LOHS.
When the laboratory findings were examined, d-dimer was found to be a significant independent risk factor for mortality, ferritin for LOHS, and AST for both mortality and LOHS. There are many studies and meta-analyses in the literature that support our results. In two different meta-analyses, increased aminotransferase levels were shown to be a risk factor for mortality (Boregowda et al. 2020; Wang et al. 2021). In another meta-analysis, the authors found a significant difference in mortality according to AST, ALT, and D-dimer levels (Loomba et al. 2022). However, there are also studies showing that AST rises more than ALT in COVID-19 patients (Bloom et al. 2021). In studies conducted with hospitalized patients in different countries, ferritin has been shown to be an indicator for predicting in-hospital mortality (Tural Onur et al. 2021; Lino et al. 2021; Deng et al. 2021; Ahmed et al. 2021). In contrast, in our study, ferritin did not significantly predict mortality as an independent factor, despite being an independent risk factor for LOHS. We determined d-dimer to be an independent risk factor for mortality, as supported by many previous studies in the literature (Sakka et al. 2020; Zhang et al. 2020; Shah et al. 2020).
In this study, a comparison between different vaccines was not made, and confounding factors, such as the onset of COVID-19 treatment in hospitalized patients, drug doses, and comorbidities, were not included in statistical analyses. In addition, the study was conducted with hospitalized patients without making any distinction according to ward or ICU admission, and no COVID-19 disease severity classification was undertaken. The most important reason for these limitations was the retrospective design, which resulted in an inability to access all related data.
Conclusion
COVID-19, a disease with a high risk of transmission that can be fatal, especially in elderly patients, has caused the deaths of millions of people across the world. Although current vaccines prevent the development of the virus, their effects when combined with treatment remain a matter of debate. In this study, the effects of treatment and vaccination on the prognosis of COVID-19 were primarily investigated. In addition to using FVP and CLQ alone and together, investigating the impact of COVID-19 vaccine dose on prognosis along with treatment and finding significant outcomes represents the rich aspect of this study and provides new information for future research. Furthermore, the association between the most common demographic and laboratory characteristics and prognosis has been investigated in the literature, and the results we found in our study support previous studies. To be prepared for another potential pandemic that may arise due to COVID-19, there is a need for further research both in Turkey and in other countries to evaluate the effects of vaccination and treatment on disease prognosis.
Data availability
Data are available from the authors upon reasonable request.
References
Adalja AA, Toner E, Inglesby TV (2020) Priorities for the US Health Community responding to COVID-19. JAMA 323(14):1343–1344. https://doi.org/10.1001/jama.2020.3413
Ahmed S, Ansar Ahmed Z, Siddiqui I, Haroon Rashid N, Mansoor M, Jafri L (2021) Evaluation of serum ferritin for prediction of severity and mortality in COVID-19—a cross sectional study. Ann Med Surg (lond) 63:102163. https://doi.org/10.1016/j.amsu.2021.02.009
Alamer A, Alrashed AA, Alfaifi M et al (2021) Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin 37(7):1085–1097. https://doi.org/10.1080/03007995.2021.1920900
Alotaibi M, Ali A, Bakhshwin D, Alatawi Y, Alotaibi S, Alhifany A, Alharthi B, Alharthi N, Alyazidi A, Alharthi Y, Alrafiah A (2021) Effectiveness and safety of favipiravir compared to hydroxychloroquine for management of Covid-19: a retrospective study. Int J Gen Med 14:5597–5606. https://doi.org/10.2147/IJGM.S329881
Alwafi H, Naser AY, Qanash S et al (2021) Predictors of length of hospital stay, mortality, and outcomes among hospitalised COVID-19 patients in Saudi Arabia: a cross-sectional study. J Multidiscip Healthc 14:839–852. https://doi.org/10.2147/JMDH.S304788
Bellan M, Patti G, Hayden E et al (2020) Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Sci Rep 10(1):20731. https://doi.org/10.1038/s41598-020-77698-4
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y (2020) Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020:ciaa478. https://doi.org/10.1093/cid/ciaa478
Birhanu A, Merga BT, Ayana GM, Alemu A, Negash B, Dessie Y (2022) Factors associated with prolonged length of hospital stay among COVID-19 cases admitted to the largest treatment center in Eastern Ethiopia. SAGE Open Med 10:20503121211070370. https://doi.org/10.1177/20503121211070366
Birtay T, Bahadir S, Kabacaoglu E, Yetiz O, Demirci MF, Genctoy G (2021) Prognosis of patients hospitalized with a diagnosis of COVID-19 pneumonia in a tertiary hospital in Turkey. Ann Saudi Med 41(6):327–335. https://doi.org/10.5144/0256-4947.2021.327
Bloom PP, Meyerowitz EA, Reinus Z, Daidone M, Gustafson J, Kim AY, Schaefer E, Chung RT (2021) Liver biochemistries in hospitalized patients with COVID-19. Hepatology 73(3):890–900. https://doi.org/10.1002/hep.31326
Boregowda U, Aloysius MM, Perisetti A, Gajendran M, Bansal P, Goyal H (2020) Serum activity of liver enzymes is associated with higher mortality in COVID-19: a systematic review and meta-analysis. Front Med (lausanne) 7:431. https://doi.org/10.3389/fmed.2020.00431
Cai Q, Yang M, Liu D et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (beijing) 6(10):1192–1198. https://doi.org/10.1016/j.eng.2020.03.007
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R (2023). Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Chakraborty I, Maity P (2020) COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ 728:138882. https://doi.org/10.1016/j.scitotenv.2020.138882
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Medrxiv. https://doi.org/10.1101/2020.03.22.20040758
Cocchio S, Zabeo F, Facchin G, Piva N, Furlan P, Nicoletti M, Saia M, Tonon M, Mongillo M, Russo F, Baldo V (2022) The effectiveness of a diverse COVID-19 vaccine portfolio and its impact on the persistence of positivity and length of hospital stays: the Veneto region’s experience. Vaccines (basel) 10(1):107. https://doi.org/10.3390/vaccines10010107
Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, Soliman S, Elbahnasawy M, Badawi R, Tageldin MA (2021) Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol 166(3):949–954
de Souza FSH, Hojo-Souza NS, Batista BDO, da Silva CM, Guidoni DL (2021) On the analysis of mortality risk factors for hospitalized COVID-19 patients: a data-driven study using the major Brazilian database. PLoS ONE 16(3):e0248580. https://doi.org/10.1371/journal.pone.0248580
Deng F, Zhang L, Lyu L, Lu Z, Gao D, Ma X, Guo Y, Wang R, Gong S, Jiang W (2021) Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Med Clin (engl Ed) 156(7):324–331. https://doi.org/10.1016/j.medcle.2020.11.015
Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8(4):e21. https://doi.org/10.1016/S2213-2600(20)30116-8
Fortunato F, Martinelli D, Lo Caputo S, Santantonio T, Dattoli V, Lopalco PL, Prato R (2021) Sex and gender differences in COVID-19: an Italian local register-based study. BMJ Open 11(10):e051506. https://doi.org/10.1136/bmjopen-2021-051506
Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76(2):428–455. https://doi.org/10.1111/all.14657
Gedik TE, Unal D, Suzan V, Bag Soytas R, Arman P, Bektan Kanat B, Ulugerger Avci G, Suna Erdincler D, Doventas A, Yavuzer H (2023) The impact of COVID-19 pandemic on the geriatric inpatient unit. Curr Med Res Opin 39(2):259–265. https://doi.org/10.1080/03007995.2022.2148460
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW (2020) Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 382(25):2411–2418. https://doi.org/10.1056/NEJMoa2012410
Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM et al (2020) Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: a retrospective observational study (COQUIMA cohort). EclinicalMedicine 28:100591. https://doi.org/10.1016/j.eclinm.2020.100591
Guo A, Lu J, Tan H, Kuang Z, Luo Y, Yang T, Xu J, Yu J, Wen C, Shen A (2021) Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. Sci Rep 11(1):7310. https://doi.org/10.1038/s41598-021-86853-4
Havers FP, Pham H, Taylor CA et al (2022) COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US states, January 2021 to April 2022. JAMA Intern Med 182(10):1071–1081. https://doi.org/10.1001/jamainternmed.2022.4299
Hernández-Galdamez DR, González-Block MÁ, Romo-Dueñas DK, Lima-Morales R, Hernández-Vicente IA, Lumbreras-Guzmán M, Méndez-Hernández P (2020) Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch Med Res 51(7):683–689. https://doi.org/10.1016/j.arcmed.2020.07.003
Ho TC, Wang YH, Chen YL, Tsai WC, Lee CH, Chuang KP, Chen YA, Yuan CH, Ho SY, Yang MH, Tyan YC (2021) Chloroquine and hydroxychloroquine: efficacy in the treatment of the COVID-19. Pathogens 10(2):217. https://doi.org/10.3390/pathogens10020217
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM (2021) Trends in COVID-19 risk-adjusted mortality rates. J Hosp Med 16(2):90–92. https://doi.org/10.12788/jhm.3552
Huang YZ, Kuan CC (2022) Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 26(5):1770–1776. https://doi.org/10.26355/eurrev_202203_28248
Huang M, Tang T, Pang P et al (2020) Treating COVID-19 with chloroquine. J Mol Cell Biol 12(4):322–325. https://doi.org/10.1093/jmcb/mjaa014
Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A (2020) The role of biomarkers in diagnosis of COVID-19—a systematic review. Life Sci 254:117788. https://doi.org/10.1016/j.lfs.2020.117788
Kokturk N, Babayigit C, Kul S et al (2021) The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients. Respir Med 183:106433. https://doi.org/10.1016/j.rmed.2021.106433
Lagunas-Rangel FA (2020) Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol 92(10):1733–1734. https://doi.org/10.1002/jmv.25819
Lino K, Guimarães GMC, Alves LS, Oliveira AC, Faustino R, Fernandes CS, Tupinambá G, Medeiros T, Silva AAD, Almeida JR (2021) Serum ferritin at admission in hospitalized COVID-19 patients as a predictor of mortality. Braz J Infect Dis 25(2):101569. https://doi.org/10.1016/j.bjid.2021.101569
Loomba RS, Villarreal EG, Farias JS, Aggarwal G, Aggarwal S, Flores S (2022) Serum biomarkers for prediction of mortality in patients with COVID-19. Ann Clin Biochem 59(1):15–22. https://doi.org/10.1177/00045632211014244
Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, Mu J, Guo J, Li W, Wang G, Gao H, Zhang Y, Lin M, Chen L, Shen S, Zhang H, Sander JW, Luo J, Chen S, Zhou D (2020) New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: a retrospective multicenter study. Epilepsia 61(6):e49–e53. https://doi.org/10.1111/epi.16524
Macchia A, Ferrante D, Angeleri P, Biscayart C, Mariani J, Esteban S, Tablado MR, de Quirós FGB (2021) Evaluation of a COVID-19 vaccine campaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw Open 4(10):e2130800. https://doi.org/10.1001/jamanetworkopen.2021.30800
Macedo A, Gonçalves N, Febra C (2021) COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol 57:14–21. https://doi.org/10.1016/j.annepidem.2021.02.012
Medetalibeyoglu A, Senkal N, Kose M, Catma Y, Bilge Caparali E, Erelel M, Oral Oncul M, Bahat G, Tukek T (2020) Older adults hospitalized with Covid-19: clinical characteristics and early outcomes from a single center in Istanbul. Turkey J Nutr Health Aging 24(9):928–937. https://doi.org/10.1007/s12603-020-1477-2
Mehraeen E, Karimi A, Barzegary A, Vahedi F, Afsahi AM, Dadras O, Moradmand-Badie B, Seyed Alinaghi SA, Jahanfar S (2020) Predictors of mortality in patients with COVID-19-a systematic review. Eur J Integr 40:101226. https://doi.org/10.1016/j.eujim.2020.101226
Mutair AA, Shamou J, Alhumaid S, Layqah L, Ahmed GY, Thoyaja K, Mohaini MA, Almahmoud S, Barry M, Khan A, Dhama K, Al-Jamea LH, Woodman A, Rabaan AA (2022) Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia. J Infect Public Health 15(4):389–394. https://doi.org/10.1016/j.jiph.2022.01.013
Nguyen NT, Chinn J, De Ferrante M, Kirby KA, Hohmann SF, Amin A (2021) Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. PLoS ONE 16(7):e0254066. https://doi.org/10.1371/journal.pone.0254066
Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y (2022) Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 27(1):6. https://doi.org/10.1186/s40001-021-00626-3
Quah P, Li A, Phua J (2020) Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care 24(1):285. https://doi.org/10.1186/s13054-020-03006-1
Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J (2022) Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand. Antibiotics (basel) 11(6):805. https://doi.org/10.3390/antibiotics11060805
Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, Group CW, Jombart T, Procter SR, Knight GM (2020) COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med 18(1):270. https://doi.org/10.1186/s12916-020-01726-3
Sakka M, Connors JM, Hékimian G, Martin-Toutain I, Crichi B, Colmegna I, Bonnefont-Rousselot D, Farge D, Frere C (2020) Association between d-dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. J Med Vasc 45(5):268–274. https://doi.org/10.1016/j.jdmv.2020.05.003
Self WH, Semler MW, Leither LM et al (2020) Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA 324(21):2165–2176. https://doi.org/10.1001/jama.2020.22240
Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, Turagam MK, Lakkireddy D, Garg J (2020) Elevated d-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. Cardiol Rev 28(6):295–302. https://doi.org/10.1097/CRD.0000000000000330
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R (2020) World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg 76:71–76. https://doi.org/10.1016/j.ijsu.2020.02.034
Solaymani-Dodaran M, Ghanei M, Bagheri M et al (2021) Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol 95:107522. https://doi.org/10.1016/j.intimp.2021.107522
Stepanova M, Lam B, Younossi E et al (2022) The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis 22(1):702. https://doi.org/10.1186/s12879-022-07657-z
Tawfik A, Alzahrani A, Alharbi S, Almitairi J, Alzahrani A, Alshehri MA, Aldughaim MS, Alothaid H (2022) Effectiveness of early favipiravir therapy in hospitalised COVID-19 patients. Adv Virol 2022:9240941. https://doi.org/10.1155/2022/9240941
Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, Wooster L, Rotter JI, Guo X, Malhotra R (2020) Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol 92(10):1875–1883. https://doi.org/10.1002/jmv.26050
Tural Onur S, Altın S, Sokucu SN, Fikri BI, Barca T, Bolat E, Toptas M (2021) Could ferritin level be an indicator of COVID-19 disease mortality? J Med Virol 93(3):1672–1677. https://doi.org/10.1002/jmv.26543
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M (2021) Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 103:62–71. https://doi.org/10.1016/j.ijid.2020.11.142
Valverde-Monge M, Cañas JA, Barroso B, Betancor D, Ortega-Martin L, Gómez-López A, Rodríguez-Nieto MJ, Mahíllo-Fernández I, Sastre J, Del Pozo V (2021) Eosinophils and chronic respiratory diseases in hospitalized COVID-19 patients. Front Immunol 12:668074. https://doi.org/10.3389/fimmu.2021.668074
Wang Y, Shi L, Wang Y, Yang H (2021) An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients. Am J Emerg Med 40:208–209. https://doi.org/10.1016/j.ajem.2020.05.063
Wang Z, Liu Y, Wei L, Ji JS, Liu Y, Liu R, Zha Y, Chang X, Zhang L, Liu Q, Zhang Y, Zeng J, Dong T, Xu X, Zhou L, He J, Deng Y, Zhong B, Wu X (2022) What are the risk factors of hospital length of stay in the novel coronavirus pneumonia (COVID-19) patients? A survival analysis in southwest China. PLoS ONE 17(1):e0261216. https://doi.org/10.1371/journal.pone.0261216
Whittaker R, Bråthen Kristofferson A, Valcarcel Salamanca B, Seppälä E, Golestani K, Kvåle R, Watle SV, Buanes EA (2022) Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients. Clin Microbiol Infect 28(6):871–878. https://doi.org/10.1016/j.cmi.2022.01.033
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://doi.org/10.1001/jama.2020.12839
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, Chen X, Chen S, Yu K, Huang Z, Hu B (2020) D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care 8:49. https://doi.org/10.1186/s40560-020-00466-z
Yuan Y, Jiao B, Qu L, Yang D, Liu R (2023) The development of COVID-19 treatment. Front Immunol 14:1125246. https://doi.org/10.3389/fimmu.2023.1125246
Zeren F, Yilanci V (2020) Analysing spatial patterns of the Covid-19 outbreak in Turkey. Bingöl Üniv İktis İdari Bilim Fak Derg 4(2):27–40. https://doi.org/10.33399/biibfad.789117
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18(6):1324–1329. https://doi.org/10.1111/jth.14859
Zhang H, Wu Y, He Y, Liu X, Liu M, Tang Y, Li X, Yang G, Liang G, Xu S, Wang M, Wang W (2022) Age-related risk factors and complications of patients with COVID-19: a population-based retrospective study. Front Med (lausanne) 8:757459. https://doi.org/10.3389/fmed.2021.757459
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
Funding
Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK). The authors have not disclosed any funding.
Author information
Authors and Affiliations
Contributions
Seyma Oncu: investigation, conceptualization, formal analysis, writing—original draft, writing—review and editing. Derya Korkmaz: conceptualization, validation, writing—review and editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no potential conflicts of interest to disclose.
Ethical approval
This study was approved by Afyonkarahisar University of Health Sciences (AFSU) Non-Interventional Research Ethics Committee (number: 07.01.2022/52). Ministry of Health (Turkey) approval number: 2021-12-22T20_29_06.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Oncu, S., Korkmaz, D. Evaluation of the relationship of treatment and vaccination with prognosis in patients with a diagnosis of COVID-19. Inflammopharmacol 32, 1817–1826 (2024). https://doi.org/10.1007/s10787-024-01457-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-024-01457-4